RE:Today's TLD1433 Shout-outs
Great post Eog.
My longterm view of the science of PDT and Dr. McFarland is that when they get more support/BTD/AA etc for use in bladder cancer it should help move things along wtih GBM (cash, researcher enthusiasm etc).
Then comes GBM. As I've said before a lot of cancer trials take a while because the current approach is as follows
- regular immune type drug (iv or oral)
- immune impact may slowly work on tumours
- results are only visible when given for a while so that can show that some patients live a few months longer. That is where a lot of cancer therapy is at. Not cures, just survival or progression free survival.
- With a GBM trial, they would like treat once and then image a month or two later to measure tumour size. Initially the dose would be low but then work up. For a disease as rapid growing as GBM if you show that Rutherin stalls or shrinks the obvious GBM on CT scan then you are gold. That would be such a massive, massive deal that it would be Fast track, BTD, AA. None of this waiting to see if the patient's live an extra few months time after ages of treatment. Almost no one has had success shrinking GBM.
Once you validate one, then one would hope that the uber-drug reference by Eog would have faster time to use as you could argue them as version 2.0 and 3.0 and so forth.
If you show one solid tumour shrinks, it would not be much to validate that any iron loving solid tumour (pretty much all of them) could be treated that way.
So overall - big things to come if we can just get there :)